![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- ย CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...
Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- ย CERo...
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (โCERoโ) an innovative immunotherapy company seeking to advance the next generation...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (โCERoโ) an innovative immunotherapy company seeking to advance the next...
CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.094 | -32.9708874079 | 0.2851 | 0.3452 | 0.165 | 12605765 | 0.20986494 | CS |
4 | -0.555 | -74.3868114194 | 0.7461 | 0.9858 | 0.165 | 5702083 | 0.27924986 | CS |
12 | -1.6489 | -89.6141304348 | 1.84 | 1.84 | 0.165 | 1912321 | 0.32148721 | CS |
26 | -5.0589 | -96.36 | 5.25 | 12.38 | 0.165 | 1789724 | 1.38156037 | CS |
52 | -5.0589 | -96.36 | 5.25 | 12.38 | 0.165 | 1789724 | 1.38156037 | CS |
156 | -5.0589 | -96.36 | 5.25 | 12.38 | 0.165 | 1789724 | 1.38156037 | CS |
260 | -5.0589 | -96.36 | 5.25 | 12.38 | 0.165 | 1789724 | 1.38156037 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions